rawpixel / iStockphoto.com
Thomas Kirkbak, chief IP litigation specialist at Danish company Lundbeck, faces challenges on several fronts, as he explains to LSIPR.
IP infringement covering pharmaceuticals typically takes place where generic companies can make the most profits, according to Thomas Kirkbak, chief IP litigation specialist and attorney-at-law at Lundbeck.
“If a lot of money can be made by entering a generic product on a certain market, my experience is that the generic companies are willing to take substantial risks of infringing the originator’s IP rights,” he says.
Kirkbak explains that a generic will usually first infringe in the US, because that is where the biggest profits can be made. This is followed by challenges to the IP rights in the UK and Germany.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
LSIPR 50 2017, Thomas Kirkbak, Lundbeck, IP litigation, generic product, generics, pharmaceutical, damages, infringement,